Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for the Treatment of ALS
SNN,
--News Direct-- --News Direct-- Kadimastem Ltd. (TASE: KDST), a well-known biotech company in the field of cellular therapy…
--News Direct-- --News Direct-- Kadimastem Ltd. (TASE: KDST), a well-known biotech company in the field of cellular therapy…
Kadimastem Ltd recently has submitted an Investigational New Drug (IND) application to the US FDA for an approval for a multi-sit…
(via NewsDirect) (TASE: KDST), a well-known biotech company in the field of cellular therapy, which is in the clinical…
The study will Determine if Repeated Dosing of AstroRx® in Three-month Intervals Achieves a Continuous Delay of the Progression…